查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575739

全球除顫器市場 - 2024-2031

Global Defibrillators Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球除顫器市場在 2023 年達到 128.8 億美元，預計到 2031 年將達到 222.9 億美元，2024-2031 年預測期間複合年成長率為 7.1%%。

除顫器是重要的醫療設備，可向心臟提供電擊或脈衝以恢復正常心跳，特別是在心臟驟停（也稱為心臟驟停 (SCA)）的情況下。當心律因心室顫動或無脈性心室心搏過速等情況而停止時，除顫器可以幫助心臟重新啟動。除非立即進行心肺復甦術 (CPR) 和使用除顫器治療，否則心臟驟停是致命的。

除顫器透過向心肌提供電擊來發揮作用。這種電擊使心臟組織的很大一部分去極化，有效地破壞導致心律不整的紊亂電活動。主要目的是重置心臟的電系統，使其恢復正常節律。除顫器針對的主要心律不整是心室顫動和無脈性心室心搏過速。

市場動態：

司機

心血管疾病 (CVD) 盛行率的增加和技術進步

全球除顫器市場的需求是由多種因素所驅動的。關鍵因素之一是心血管疾病（CVD）盛行率的增加和技術的進步。心血管疾病（CVD）是全世界最主要的死因。冠狀動脈疾病和心臟衰竭等心血管疾病（CVD）發生率的增加是推動去顫器市場成長的主要因素。

根據世界衛生組織 2024 年 5 月的資料，心血管疾病（CVD）是歐洲地區殘疾和過早死亡的主要原因，佔年度死亡人數的 42.5% 以上，相當於每天約有 10,000 人死亡。根據世界衛生組織/歐洲的報告，該地區男性死於心血管疾病的可能性是女性的近 2.5 倍。

此外，還存在明顯的地理差異；東歐和中亞因心血管疾病而年輕（30 歲至 69 歲）死亡的可能性幾乎是西歐的五倍。由於心血管疾病 (CVD) 是歐洲死亡和殘疾的首要原因，因此迫切需要在心臟緊急情況下立即進行除顫。

此外，除顫器技術的持續創新正在顯著提高設備效率和使用者友善性，這對於改善心臟緊急情況下的患者治療效果至關重要。現代除顫器，特別是植入式心臟復律去顫器(ICD) 和自動體外除顫器(AED)，現在融入了先進的功能，有助於更好地監測和治療有心臟驟停風險的患者。

此外，意識計劃和推出創新產品等政府措施正在推動該市場的成長。例如，2023 年 7 月，北方邦政府宣布了一項重大舉措，透過在所有政府大樓、商場和其他公共場所（包括北方邦秘書處）安裝自動體外心臟去顫器 (AED) 來改善公共衛生。該計劃旨在為發生心臟驟停的個人提供必要的急救。

此外，2023年1月，邁瑞宣布推出新一代BeneHeart系列除顫器，特別是BeneHeart D60和D30型號。這些先進的設備旨在透過提供卓越的可靠性、全面的診斷功能和監測工具來提高復甦標準。這些除顫器的推出旨在為院內和院前緊急情況提供完整的品質改進解決方案。

限制

產品召回、設備成本高、與設備使用相關的擔憂、缺乏熟練專業人員以及監管挑戰等因素預計將阻礙市場發展。

細分市場分析

全球除顫器市場根據產品類型、年齡層、最終用戶和地區進行細分。

體外去顫器部分約佔全球除顫器市場佔有率的73.3%

預計體外除顫器領域將在預測期內佔據最大的市場佔有率。體外心臟去顫器是一種醫療設備，旨在對心臟進行電擊，以在危及生命的心律不整（例如心室顫動和無脈性室性心動過速）期間恢復其正常節律。

這些設備對於治療心臟驟停 (SCA) 至關重要，這種情況是指心臟意外停止有效運作。體外去顫器包括手動體外心臟去顫器、穿戴式心臟復律去顫器和自動體外去顫器（AED）。

此外，該地區的主要參與者、產品發布和宣傳計劃有助於推動該細分市場的市場成長。例如，2024 年 3 月，全球領先的醫療科技公司 Stryker 參加了在印度加爾各答 ITC 皇家孟加拉會議中心舉行的 Criticare 全國會議。在本次活動中，史賽克推出並展示了兩款創新產品：LIFEPAK CR2自動體外心臟去顫器（AED）和專為緊急患者疏散設計的疏散椅。

LIFEPAK CR2 是一款創新除顫器，可讓救援人員在心臟驟停 (SCA) 緊急情況下提供高品質的心肺復甦術並立即提供電擊。這種革命性的設備旨在增強救援人員為心臟驟停的受害者提供救生護理的能力。

同樣，2024 年 1 月，Speedy Hire 啟動了一項救生計劃，為其遍布英國的工程車配備自動體外心臟去顫器 (AED)。此次部署首先安裝 18 個除顫器，並計劃將其擴展到 Speedy Hire 工程師的貨車中的 300 多個攜帶式設備。該計劃旨在解決英國每年有超過 30,000 人發生院外心臟驟停、存活率不足 10% 的令人擔憂的統計數據。 Speedy Hire 旨在透過在貨車中提供 AED 來增強緊急情況下的即時回應能力，確保在需要時隨時提供協助。

市場地理分析

北美約佔全球除顫器市場佔有率的43.7%

由於心臟病、心臟衰竭和冠心病等心血管疾病的發病率不斷增加，北美地區預計將在預測期內佔據最大的市場佔有率，這是北美市場成長的重要推動力。

心臟病是美國男性和女性死亡的主要原因。 2022 年，心血管疾病奪走了 702,880 人的生命，這意味著每 33 秒就有 1 人死亡，約佔全國每 5 人死亡人數中就有 1 人死於心血管疾病。

此外，意識宣傳活動和政府措施提高了自動體外心臟去顫器 (AED) 的重要性，推動了北美市場的成長。美國許多州已頒布法律，強制在特定公共場所安裝 AED，包括高速公路休息區、政府大樓、公共安全車輛、飯店、緊急護理中心和零售健康診所。

此外，在該地區，大量關鍵參與者的存在、先進的醫療基礎設施、技術進步以及產品發布和批准將推動該市場的成長。例如，2023 年10 月，美敦力(Medtronic) 的Aurora 血管外植入式心臟復律去顫器(EV-ICD) 獲得FDA 批准，這是一種創新設備，旨在治療心律異常和預防心臟驟停(SCA)。這種創新的除顫器代表了心臟護理技術的重大進步。

此外，2023 年 1 月，Avive Solutions 的創新 Avive AED（一種獨特的自動體外心臟去顫器 (AED)）獲得了美國食品藥物管理局 (FDA) 的上市前批准 (PMA)。此次批准標誌著心臟急救技術的重大進步。

Avive AED 是一款開創性設備，它將蜂窩、WiFi、GPS 和藍牙連接整合到緊湊的手持式設備中。這套連接功能為 Avive 突破性的 REALConnect 技術提供支持，該技術旨在透過與 RapidSOS 的合作與 911 急診中心無縫連接。因此，該設備可以將關鍵事件資料即時傳輸給 911 調度員、緊急醫療服務 (EMS) 和醫療保健專業人員，從而增強態勢感知並最佳化緊急應變工作。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 心血管疾病 (CVD) 盛行率的增加和技術進步
    • 限制
      • 產品召回
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章：依產品類型

  • 植入式心臟復律去顫器 (ICD)
    • 經靜脈植入式心臟復律去顫器 (T-ICD)
    • 皮下植入式心臟復律去顫器 (S-ICD)
    • 心臟再同步治療去顫器 (CRT-D)
  • 體外去顫器
    • 手動體外心臟去顫器
    • 穿戴式心臟復律去顫器
    • 自動體外去顫器 (AED)
      • 半自動 AED
      • 全自動 AED

第 7 章：按年齡層

  • 兒科
  • 成年人

第 8 章：最終用戶

  • 醫院
  • 心臟中心
  • 家庭護理設置
  • 其他

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Medtronic
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Boston Scientific Corporation
  • Abbott
  • Koninklijke Philips NV
  • Stryker
  • NIHON KOHDEN CORPORATION
  • Mindray Medical India Pvt. Ltd.
  • MicroPort Scientific Corporation.
  • ZOLL Medical Corporation
  • Biotronik (*LIST NOT EXHAUSTIVE)

第 12 章：附錄

簡介目錄
Product Code: MD780

Report Overview

The Global Defibrillators Market reached US$ 12.88 billion in 2023 and is expected to reach US$ 22.29 billion by 2031 growing with a CAGR of 7.1%% during the forecast period 2024-2031.

Defibrillators are critical medical devices that deliver an electric shock or pulse to the heart to restore a normal heartbeat, particularly in cases of cardiac arrest, also known as sudden cardiac arrest (SCA). When the heart's rhythm ceases due to conditions such as ventricular fibrillation or pulseless ventricular tachycardia, a defibrillator can help restart the heart. A sudden cardiac arrest is fatal unless treated immediately with cardiopulmonary resuscitation (CPR) and the use of a defibrillator.

Defibrillators function by delivering an electric shock to the heart muscle. This shock depolarizes a significant portion of the heart tissue, effectively disrupting the disordered electrical activity that leads to arrhythmias. The primary aim is to reset the heart's electrical system, enabling it to regain a normal rhythm. The main arrhythmias that defibrillators target are ventricular fibrillation and pulseless ventricular tachycardia.

Market Dynamics: Drivers

Increasing prevalence of cardiovascular diseases (CVDs) and technological advancements

The demand for the global defibrillators market is driven by multiple factors. One of the key factors is the increasing prevalence of cardiovascular diseases (CVDs) and technological advancements. Cardiovascular diseases (CVDs) are the foremost cause of death worldwide. The increasing occurrence of cardiovascular diseases (CVDs), such as coronary artery disease and heart failure, is a major factor driving the growth of the defibrillator market.

According to the WHO data in May 2024, Cardiovascular diseases (CVDs) are the primary cause of disability and premature death in the European Region, accounting for over 42.5% of all annual deaths, which translates to approximately 10,000 fatalities each day. As per the report from WHO/Europe, men in this region are nearly 2.5 times more likely to succumb to CVD compared to women.

Additionally, there is a marked geographic disparity; the likelihood of dying young (between the ages of 30 and 69) from a CVD is almost five times greater in Eastern Europe and Central Asia than in Western Europe. With cardiovascular diseases (CVDs) being the foremost cause of death and disability in Europe, there is an urgent requirement for immediate access to defibrillation during cardiac emergencies.

Moreover, continuous innovations in defibrillator technology are significantly enhancing device efficiency and user-friendliness, which is crucial for improving patient outcomes during cardiac emergencies. Modern defibrillators, particularly Implantable Cardioverter Defibrillators (ICDs) and Automated External Defibrillators (AEDs), now incorporate advanced features that facilitate better monitoring and treatment of patients at risk of sudden cardiac arrest.

In addition, government initiatives such as awareness programs and the introduction of innovative product launches are driving this market growth. For instance, in July 2023, the Uttar Pradesh government announced a significant initiative to improve public health by installing Automated External Defibrillators (AEDs) in all government buildings, malls, and other public places, including the Uttar Pradesh Secretariat. This initiative aims to provide essential first aid to individuals experiencing cardiac arrest.

Also, in January 2023, Mindray announced the launch of its next-generation BeneHeart series defibrillators, specifically the BeneHeart D60 and D30 models. These advanced devices are designed to elevate the standards of resuscitation by offering superior reliability, comprehensive diagnostic capabilities, and monitoring tools. The introduction of these defibrillators aims to provide a complete quality improvement solution for both in-hospital and pre-hospital emergencies.

Restraints

Factors such as product recalls, the high cost of devices, concerns associated with the usage of devices, lack of skilled professionals, and regulatory challenges are expected to hamper the market.

Market Segment Analysis

The global defibrillators market is segmented based on product type, age group, end-user, and region.

The external defibrillators segment accounted for approximately 73.3% of the global defibrillators market share

The external defibrillators segment is expected to hold the largest market share over the forecast period. External defibrillators are medical devices designed to deliver an electric shock to the heart to restore its normal rhythm during life-threatening cardiac arrhythmias, such as ventricular fibrillation and pulseless ventricular tachycardia.

These devices are essential for treating sudden cardiac arrest (SCA), a condition where the heart unexpectedly stops functioning effectively. External defibrillators include manual external defibrillators, wearable cardioverter defibrillators, and automated external defibrillators (AEDs).

Moreover, key players in the region, product launches, and awareness programs help to propel this segment's growth in the market. For instance, in March 2024, Stryker, a leading global medical technology company, participated in the Criticare National Conference, which took place at the ITC Royal Bengal in Kolkata, India. During this event, Stryker launched and showcased two innovative products: LIFEPAK CR2 automated external defibrillator (AED) and the Evacuation Chair designed for emergency patient evacuation.

The LIFEPAK CR2 is an innovative defibrillator that empowers rescuers to deliver high-quality CPR and provide immediate shocks during sudden cardiac arrest (SCA) emergencies. This revolutionary device is designed to enhance the ability of rescuers to provide life-saving care to victims of sudden cardiac arrest.

Similarly, in January 2024, Speedy Hire initiated a life-saving program to equip its engineer vans across the UK with Automated External Defibrillators (AEDs). The rollout starts with the installation of 18 defibrillators, with plans to expand this to over 300 portable devices in the vans of Speedy Hire's engineers. This initiative aims to address the concerning statistic that more than 30,000 individuals in the UK suffer from out-of-hospital cardiac arrests annually, with less than 10% surviving. By providing AEDs in their vans, Speedy Hire intends to enhance immediate response capabilities during emergencies, ensuring that help is readily available when needed.

Market Geographical Analysis

North America accounted for approximately 43.7% of the global defibrillators market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing occurrence of cardiovascular diseases, such as heart attack, heart failure, and coronary heart disease, which is a significant driver of market growth in North America.

Heart disease is the primary cause of mortality for men, and women, in the United States. In 2022, cardiovascular disease claimed the lives of 702,880 people, which translates to one death every 33 seconds and accounts for approximately one out of every five deaths nationwide.

Moreover, awareness campaigns and government initiatives propel the significance of automated external defibrillators (AEDs) fueling market growth in North America. Numerous states in the U.S. have enacted laws mandating the installation of AEDs in specific public locations, including highway rest areas, government buildings, public safety vehicles, hotels, urgent care centers, and retail health clinics.

Additionally, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, technological advancements, and product launches & approvals would propel this Market growth. For instance, in October 2023, Medtronic received FDA approval for its Aurora Extravascular Implantable Cardioverter Defibrillator (EV-ICD), an innovative device designed to treat abnormal heart rhythms and prevent sudden cardiac arrest (SCA). This innovative defibrillator represents a significant advancement in cardiac care technology.

Also, in January 2023, Avive Solutions received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA) for its innovative Avive AED, a unique Automated External Defibrillator (AED). This approval signifies a major advancement in cardiac emergency response technology.

The Avive AED is a pioneering device that integrates cellular, WiFi, GPS, and Bluetooth connectivity into a compact, handheld format. This suite of connectivity features powers Avive's groundbreaking REALConnect Technology, which is designed to seamlessly connect with 911 emergency centers through a collaboration with RapidSOS. As a result, the device can transmit critical incident data to 911 dispatchers, emergency medical services (EMS), and healthcare professionals in real-time, enhancing situational awareness and optimizing emergency response efforts.

Market Segmentation

By Product Type

Implantable Cardioverter Defibrillators (ICDs)

Transvenous Implantable Cardioverter Defibrillators (T-ICDs)

Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs)

Cardiac Resynchronization Therapy Defibrillators (CRT-D)

External Defibrillators

Manual External Defibrillators

Wearable Cardioverter Defibrillators

Automated External Defibrillators (AEDs)

Semi-Automated AEDs

Fully Automated AEDs

By Age Group

Pediatrics

Adults

By End-User

Hospitals

Cardiac Centers

Homecare Settings

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the defibrillators market include Medtronic, Boston Scientific Corporation, Abbott, Koninklijke Philips N.V., Stryker, NIHON KOHDEN CORPORATION, Mindray Medical India Pvt. Ltd., MicroPort Scientific Corporation., ZOLL Medical Corporation, and Biotronik among others.

Key Developments

In June 2024, the launch of the first-ever Hato Hone St John branded defibrillators represents a significant advancement in emergency cardiac care technology. These new Automated External Defibrillators (AEDs), developed in partnership with medical technology manufacturer ViVest, are designed to deliver a shock to a patient in as little as seven seconds, which is crucial during sudden cardiac arrest (SCA) situations.

In May 2024, London Hearts, a leading defibrillator charity in the UK, announced the launch of a new scheme aimed at making defibrillators more accessible and affordable to communities across the country. The charity provides funding through grants to help organizations and communities acquire these life-saving devices. The scheme is a significant step towards making defibrillators more affordable and widely available throughout the UK.

In October 2023, MicroPort CRM announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICDs) and INVICTA defibrillation lead in Japan. Both devices are MRI conditional at 1.5T and 3T when implanted as a system. This advanced technology ensures low current consumption, leading to a predicted lifespan that is up to 8 years longer than other ICD devices. Additionally, the ULYS incorporates the PARAD+ arrhythmia discrimination algorithm, which has been clinically proven to have the lowest rate of inappropriate shocks.

Why Purchase the Report?

To visualize the global defibrillators market segmentation based on product type, age group, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the defibrillators market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global defibrillators market report would provide approximately 62 tables, 51 figures, and 183 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Cardiovascular Diseases (CVDs) And Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Product Recalls
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Implantable Cardioverter Defibrillators (ICDs)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Transvenous Implantable Cardioverter Defibrillators (T-ICDs)
    • 6.2.4. Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs)
    • 6.2.5. Cardiac Resynchronization Therapy Defibrillators (CRT-D)
  • 6.3. External Defibrillators
    • 6.3.1. Manual External Defibrillators
    • 6.3.2. Wearable Cardioverter Defibrillators
    • 6.3.3. Automated External Defibrillators (AEDs)
      • 6.3.3.1. Semi-Automated AEDs
      • 6.3.3.2. Fully Automated AEDs

7. By Age Group

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 7.1.2. Market Attractiveness Index, By Age Group
  • 7.2. Pediatrics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adults

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiac Centers
  • 8.4. Homecare Settings
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Medtronic*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Boston Scientific Corporation
  • 11.3. Abbott
  • 11.4. Koninklijke Philips N.V.
  • 11.5. Stryker
  • 11.6. NIHON KOHDEN CORPORATION
  • 11.7. Mindray Medical India Pvt. Ltd.
  • 11.8. MicroPort Scientific Corporation.
  • 11.9. ZOLL Medical Corporation
  • 11.10. Biotronik (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us